Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Vernon Holers to Protein Binding

This is a "connection" page, showing publications Vernon Holers has written about Protein Binding.

 
Connection Strength
 
 
 
0.851
 
  1. Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147.
    View in: PubMed
    Score: 0.115
  2. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014; 32:433-59.
    View in: PubMed
    Score: 0.077
  3. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013 May; 123(5):2218-30.
    View in: PubMed
    Score: 0.073
  4. Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, Arend WP, Holers VM. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol. 2013 Apr 01; 190(7):3560-9.
    View in: PubMed
    Score: 0.072
  5. Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. 2013 Jan; 53(1-2):99-110.
    View in: PubMed
    Score: 0.069
  6. Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28; 119(26):6307-16.
    View in: PubMed
    Score: 0.068
  7. Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J Biol Chem. 2010 Aug 27; 285(35):27251-27258.
    View in: PubMed
    Score: 0.060
  8. Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J Biol Chem. 2009 Apr 03; 284(14):9513-20.
    View in: PubMed
    Score: 0.054
  9. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol. 2006 Jul 01; 177(1):383-94.
    View in: PubMed
    Score: 0.045
  10. Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry. 2001 May 22; 40(20):5931-41.
    View in: PubMed
    Score: 0.032
  11. Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J Control Release. 2019 05 28; 302:181-189.
    View in: PubMed
    Score: 0.028
  12. Narang A, Qiao F, Atkinson C, Zhu H, Yang X, Kulik L, Holers VM, Tomlinson S. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation. 2017 06 19; 14(1):120.
    View in: PubMed
    Score: 0.024
  13. Renner B, Ferreira VP, Cortes C, Goldberg R, Ljubanovic D, Pangburn MK, Pickering MC, Tomlinson S, Holland-Neidermyer A, Strassheim D, Holers VM, Thurman JM. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 2011 Jul; 80(2):165-73.
    View in: PubMed
    Score: 0.016
  14. Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol. 2010 Dec 10; 404(4):697-710.
    View in: PubMed
    Score: 0.015
  15. Renner B, Coleman K, Goldberg R, Amura C, Holland-Neidermyer A, Pierce K, Orth HN, Molina H, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Thurman JM. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol. 2010 Sep 01; 185(5):3086-94.
    View in: PubMed
    Score: 0.015
  16. Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN, Geisbrecht BV, Lambris JD. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol. 2009 Aug 15; 183(4):2565-74.
    View in: PubMed
    Score: 0.014
  17. Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol. 2008 Nov; 82(22):11217-27.
    View in: PubMed
    Score: 0.013
  18. Li K, Okemefuna AI, Gor J, Hannan JP, Asokan R, Holers VM, Perkins SJ. Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2. J Mol Biol. 2008 Dec 05; 384(1):137-50.
    View in: PubMed
    Score: 0.013
  19. Young KA, Chen XS, Holers VM, Hannan JP. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). J Biol Chem. 2007 Dec 14; 282(50):36614-25.
    View in: PubMed
    Score: 0.012
  20. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol. 2007 Sep 15; 179(6):4101-9.
    View in: PubMed
    Score: 0.012
  21. Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol. 2006 Nov; 13(11):996-1001.
    View in: PubMed
    Score: 0.012
  22. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ, McDonnell JM. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med. 2005 Sep 19; 202(6):751-60.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)